Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039424 · ClinicalTrials.gov registry record · NA
Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms Trial
A NA study of Gastroparesis, sponsored by Matthew Allemang.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05039424: Active NA study of Gastroparesis, sponsored by Matthew Allemang.
NCT05039424 is a NA study of Gastroparesis that is active but no longer recruiting, run by Matthew Allemang. The registered enrollment target is 100 participants, below the 300-participant average among 44 other Gastroparesis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05039424, a NA study of Gastroparesis, is active but no longer recruiting, sponsored by Matthew Allemang.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized clinical trial comparing endoscopic per-oral pyloromyotomy (POP) versus a control sham intervention (diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption) in patients with medically refractory gastroparesis.
Primary Outcome
Change in Gastroparesis Cardinal Symptom Index (GCSI) at Baseline to 12 weeks post-procedure. Possible scores range from 0 (None) to 5 (Very Severe).
Conditions Studied
Interventions
- PROCEDURE Endoscopic per-oral pyloromyotomy (POP)
- PROCEDURE Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT05039424 still lists
NCT05039424 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 300-participant average among 44 other Gastroparesis trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Endoscopic per-oral pyloromyotomy (POP) is the first listed.
NCT05039424 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05039424 about?
NCT05039424 is a clinical study titled "Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms Trial". A randomized clinical trial comparing endoscopic per-oral pyloromyotomy (POP) versus a control sham intervention (diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption) in patients with medically refractory gastroparesis.
What is the current status of trial NCT05039424?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-02-23. Estimated completion is 2026-07.
What conditions does trial NCT05039424 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT05039424?
The interventions under investigation include: Endoscopic per-oral pyloromyotomy (POP) (PROCEDURE), Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption (PROCEDURE).
Who is sponsoring clinical trial NCT05039424?
This trial is sponsored by Matthew Allemang, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039424 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05039424's enrollment target sits among peer trials
100 19th of 44 higher than 26 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
RECRUITING · NA
-
Transpyloric Stenting As a Predictor for G-POEM for Refractory Gastroparesis
RECRUITING · NA
-
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
RECRUITING · NA
-
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI